Clinical Trial Update: A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase II trial of ceritinib (LDK378) for ROS1/ALK-overexpressed advanced intrahepatic or hilar cholangiocarcinoma has been terminated. The document provides l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Hilar Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Zykadia (ceritinib)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Cholangiocarcinoma | Phase 2 | Status: TERMINATED